A Phase I/II Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma.

Trial Profile

A Phase I/II Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma.

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Carfilzomib (Primary) ; Dexamethasone; Lenalidomide; Vorinostat
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Acronyms QUAD
  • Most Recent Events

    • 28 Aug 2014 According to the ClinicaTrilas.gov record, planned end date changed from 1 Feb 2015 to 1 Aug 2015.
    • 22 Nov 2013 Planned End Date changed from 1 Dec 2013 to 1 Feb 2015 as reported by ClinicalTrials.gov.
    • 22 May 2013 Interim results will be presented at the 18th Congress of the European Hematology Association (EHA).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top